Sugi Predict

Sugi Predict / Compounds / SCHEMBL6472013

SCHEMBL6472013

SCHEMBL6472013

Nc1ccccc1-c1nn[nH]n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 3/20 1.00
▸ ALDH1A1 P00352 3/20 0.73
▸ L3MBTL1 Q9Y468 2/20 0.73
▸ MEN1 O00255 1/20 0.73
▸ KMT2A Q03164 1/20 0.73
▸ PBRM1 Q86U86 1/20 0.61
▸ GAA P10253 1/20 0.61
▸ LDHA P00338 1/20 0.61
▸ GPR35 Q9HC97 2/20 0.59
▸ HPGDS O60760 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.47
▸ ADH5 P11766 1/20 0.47
▸ XDH P47989 2/20 0.46
▸ PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2645793 0.76 MEN1 (0.73) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL30153550 0.76 MEN1 (0.80) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2645790 0.76 ALDH1A1 (0.73) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3397464 0.76 ALDH1A1 (0.73) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL14262602 0.76 MEN1 (0.73) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL14844440 0.76 ALDH1A1 (0.73) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL8429622 0.76 GAA (1.00) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL8294486 0.76 LDHA (1.00) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL4206359 0.76 PBRM1 (1.00) IDO1ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL8294492 0.76 ALDH1A1 (0.73) IDO1ALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11603349-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD (AU) 2023-03-14 — — US disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 — — US disclosed
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD (AU) 2021-08-12 — — US disclosed
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD (AU) 2021-08-12 — — US disclosed
US-11014873-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD. (AU) 2021-05-25 — — US disclosed
US-11014873-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD. (AU) 2021-05-25 — — US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 — — US disclosed
WO-2020219729-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-10-29 — — WO disclosed
US-20200055814-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. 2020-02-20 — — US disclosed
WO-2018144620-A9 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD. (AU) 2019-01-24 — — WO disclosed
WO-2018144620-A9 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD. (AU) 2019-01-24 — — WO disclosed
WO-2018204532-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2018-11-08 — — WO disclosed
WO-2018144620-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2018-08-09 — — WO disclosed
WO-2018144620-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2018-08-09 — — WO disclosed
EP-1646636-B1 PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES NOVARTIS AG (CH) 2009-12-02 — — EP disclosed
EP-1569908-A2 PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2005-09-07 — — EP disclosed
CN-1558762-A Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer ŵ��Ų�ڿ˹�˾ 2004-12-29 — — CN disclosed
WO-2004046113-A2 PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603349-B2 Anti-fibrotic compounds TGFB1, SMAD3, TGFB2 IDO1 1904/4885ALDH1A1 1274/4885L3MBTL1 4340/4885
US-11192865-B2 Benzosulfonyl compounds YAP1, TEAD2, TEAD1 IDO1 3350/4885ALDH1A1 2161/4885L3MBTL1 1250/4885
US-11186554-B2 Non-fused tricyclic compounds YAP1, MYC, TEAD2 IDO1 3967/4885ALDH1A1 3497/4885L3MBTL1 1906/4885
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS TGFB1, SMAD3, TGFB2 IDO1 1904/4885ALDH1A1 1274/4885L3MBTL1 4340/4885
US-11014873-B2 Anti-fibrotic compounds TGFB1, SMAD3, SMAD2 IDO1 1968/4885ALDH1A1 1184/4885L3MBTL1 4373/4885
US-20200055814-A1 ANTI-FIBROTIC COMPOUNDS TGFB1, SMAD3, SMAD2 IDO1 2398/4885ALDH1A1 1967/4885L3MBTL1 4118/4885
US-20200354325-A1 BENZOSULFONYL COMPOUNDS YAP1, TEAD2, TEAD1 IDO1 3350/4885ALDH1A1 2161/4885L3MBTL1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.